In Brief
This article was originally published in The Rose Sheet
Executive Summary
P&G Trims Management
You may also be interested in...
P&G Shuffles Beauty, Grooming Heads Upon Bergh’s Departure
Management changes continue at Procter & Gamble, with the announcement of further shuffling within the firm’s beauty and grooming division.
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.